VP
Insider
Vijay Satyanand Pande
DirectorVijay Satyanand Pande (Director) filed 2 Form 4 reports in the past 24 months (2 purchases, 0 sales), most often in BioAge Labs, Inc. (BIOA). Across 2 priced purchase filings, the average 21-session return was +22.4% from execution and +22.7% from disclosure (delay-adjusted; derived). The largest single filing was $16.2M of BIOA (900,000 sh × $18.00, as filed), executed Sep 27 2024.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+22.4%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+22.7%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
1d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$4.3M
shares × price, as filed
Last traded
Oct 3 2024
Filed Oct 3 2024
Median ADV $8.8M across their filed names
Open performance→Volume by month
Buys $4.3M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 24 months
Most traded names
BIOA
BioAge Labs, Inc.
BIOA · 2 buys · 0 sells
2 filings
Recent filings
BIOAPURCHASE
BioAge Labs, Inc.
View filing →
$4.3M219,195 sh across 3 lots
Exec Oct 1 2024
Filed Oct 3 2024 · 5:30 PM ET BIOAPURCHASE BioAge Labs, Inc. View filing → $16.2M
900,000 sh × $18.00
Exec Sep 27 2024
Filed Sep 27 2024 · 5:30 PM ET